Calcium oxalate crystal-induced kidney injury (COC-KI) is characterized by excessive oxidative stress and inflammation. Nanozymes can partially mitigate COC-KI through superoxide dismutase (SOD)- and catalase (CAT)-like activities, but their therapeutic efficacy is often compromised by the coexisting peroxidase (POD)- and oxidase (OXD)-like activities, which may paradoxically generate reactive oxygen species (ROS). Additionally, the lack of targeted delivery remains another challenge. To overcome these limitations together, metal-organic framework (MOF)-based nanozyme PCN222-Mn (PM), which exhibits prominent SOD- and CAT-like activities with negligible POD/OXD-like activities, was chosen for the treatment of COC-KI. To achieve precise renal targeting, we functionalized PM with hyaluronic acid (HA), yielding PCN222-Mn@HA (PMH). Both in vitro and in vivo studies demonstrated that PMH effectively accumulated in injured renal tubular epithelial cells (RTECs) and provided superior protection against COC-KI. Mechanistic investigation via RNA sequencing revealed that PMH exerted its renoprotective effects primarily by suppressing NF-κB signaling, which in turn downregulated the expression of NLRP3 and MCP-1, thereby inhibiting inflammasome activation and macrophage recruitment. Collectively, this work proposes a novel and effective targeted nanozyme strategy for the treatment of COC-KI.